Principia Biopharma Inc (PRNB) Stock Price, Forecast & Analysis

NASDAQ:PRNB

100.05
+0.1 (+0.1%)
At close: Sep 25, 2020
100.02
-0.03 (-0.03%)
After Hours: 9/25/2020, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

PRNB Key Statistics, Chart & Performance

Key Statistics
Market Cap3.32B
Revenue(TTM)50.00M
Net Income(TTM)-68.91M
Shares33.21M
Float9.50M
52 Week High101.89
52 Week Low25.35
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.41
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
PRNB short term performance overview.The bars show the price performance of PRNB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60 80

PRNB long term performance overview.The bars show the price performance of PRNB in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150 200

The current stock price of PRNB is 100.05 null. In the past month the price decreased by -0.81%. In the past year, price increased by 248.73%.

Principia Biopharma Inc / PRNB Daily stock chart

PRNB Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to PRNB. When comparing the yearly performance of all stocks, PRNB is one of the better performing stocks in the market, outperforming 98.45% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
PRNB Full Technical Analysis Report

PRNB Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to PRNB. PRNB has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PRNB Full Fundamental Analysis Report

PRNB Financial Highlights

Over the last trailing twelve months PRNB reported a non-GAAP Earnings per Share(EPS) of -2.41. The EPS decreased by -3112.5% compared to the year before.


Industry RankSector Rank
PM (TTM) -137.82%
ROA -17.85%
ROE N/A
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%10.71%
Sales Q2Q%66.67%
EPS 1Y (TTM)-3112.5%
Revenue 1Y (TTM)-37.39%
PRNB financials

PRNB Forecast & Estimates


Analysts
Analysts82.8
Price TargetN/A
EPS Next Y-33.49%
Revenue Next YearN/A
PRNB Analyst EstimatesPRNB Analyst Ratings

PRNB Ownership

Ownership
Inst Owners0.02%
Ins Owners6.47%
Short Float %N/A
Short RatioN/A
PRNB Ownership

About PRNB

Company Profile

Principia Biopharma Inc. is a clinical stage biopharmaceutical company. It offers reversible covalent small molecule drugs for the treatment of cancers. The company's product pipeline consists of PRN1008, PRN1371 and PRN2246 which are in clinical stage. Principia Biopharma Inc. is based in San Francisco, United States.

Company Info

Principia Biopharma Inc

220 East Grand Avenue

SOUTH SAN FRANCISCO CA 94080

CEO: Martin Babler

Phone: 650-416-7700

Principia Biopharma Inc / PRNB FAQ

What does Principia Biopharma Inc do?

Principia Biopharma Inc. is a clinical stage biopharmaceutical company. It offers reversible covalent small molecule drugs for the treatment of cancers. The company's product pipeline consists of PRN1008, PRN1371 and PRN2246 which are in clinical stage. Principia Biopharma Inc. is based in San Francisco, United States.


What is the current price of PRNB stock?

The current stock price of PRNB is 100.05 null. The price increased by 0.1% in the last trading session.


What is the dividend status of Principia Biopharma Inc?

PRNB does not pay a dividend.


What is the ChartMill rating of Principia Biopharma Inc stock?

PRNB has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Should I buy PRNB stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PRNB.